December 7, 2018 — New data from the Phase 3 CASSINI study showed a 60 percent reduction of venous thromboembolism (VTE ...
Pharmaceuticals
This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.
December 07, 2018
November 30, 2018 — Healthcare technology company Livongo recently announced the launch of its Applied Health Signals ...
November 30, 2018
November 16, 2018 — A research team led by scientists and doctors in Leicester and the Netherlands has shown that a ...
November 19, 2018
November 15, 2018 — AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes ...
November 15, 2018
Deepak L. Bhatt, M.D., executive director of the interventional cardiovascular program, Brigham and Women’s Hospital ...
November 13, 2018
November 13, 2018 — A study in the current edition of the New England Journal of Medicine1 shows that a particular ...
November 13, 2018
November 6, 2018 – Initial results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) ...
November 07, 2018
November 1, 2018 — A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes ...
November 01, 2018
October 31, 2018 — Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects ...
October 31, 2018
October 31, 2018 — Recent statin and medication advances have led some researchers to suggest surgical treatments for ...
October 31, 2018
October 17, 2018 — The U.S. Food and Drug Administration (FDA) has cleared an additional indication for rivaroxaban ...
October 17, 2018
October 11, 2018 — Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance ...
October 11, 2018
October 4, 2018 — Pulmonary artery denervation (PADN) is associated with significant improvements in hemodynamic and ...
October 04, 2018
Ashish Pershad, M.D., medical director, structural heart program, Banner University Medical Heart Institute, Phoenix ...
October 01, 2018
September 7, 2018 — The antithrombin drug rivaroxaban does not reduce the risk of a composite endpoint of survival ...
September 07, 2018© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now